Gabriella Egeo
Via Della Pisana 235
Rome, 00163, Italy
Rome, 00163, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.
Journal: Neurology and therapy
Published: July 23, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.
Journal: Cephalalgia : an international journal of headache
Published: June 19, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: May 27, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.
Journal: Neurology and therapy
Published: March 18, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: January 28, 2026
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.
Journal: The journal of headache and pain
Published: December 20, 2025
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.
Journal: The journal of headache and pain
Published: December 20, 2025
Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study.
Journal: Journal of neurology
Published: August 20, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).
Journal: The journal of headache and pain
Published: July 28, 2025
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.
Journal: The journal of headache and pain
Published: April 20, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).
Journal: Journal of neurology
Published: March 15, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.
Journal: Journal of neurology
Published: December 08, 2024
Last Updated: 09/26/2026